摘要
目的研究胸腺肽a1对肾移植术后巨细胞病毒(CMV)肺炎的治疗效果和不良反应。方法肾移植术后CMV肺炎患者46例分为两组,组Ⅰ单独使用抗病毒药更昔洛韦,组Ⅱ联合应用胸腺肽a1和抗病毒药。结果46例患者总存活率56.52%(26/46),组Ⅱ存活率72.73%(16/22)明显高于组Ⅰ患者的41.67%(10/24)(P<0.05),两组各有1例发生急性排斥反应。结论胸腺肽a1联合抗病毒药可提高CMV肺炎的治愈率,是安全有效的抗CMV病毒肺炎的疗法。
[Objctive] To study the therapeutic effect and side effect of thymosin al on cytomegalovirus pneumonia in kidney transplant recipients. [Methods] 46 patients with cytomegalovirus pneumonia following kidney transplantation were divided into two groups. Group Ⅰwas (n =24) administered with ganciclovir intravenously and group Ⅱ (n =22)eras administered with thymosin alby subcutaneous injection and combined with ganciclovir. [Results] Among 46 patients, the survival rate was 56.52%(26/46). The survival rate of group Ⅱ was higher than that of group Ⅰ and there was significant diffcrence (72,73% vs 41.67%, P 〈0.05). 1 patient in each group developed acute rejection. No obvious side effects were observed. [Conclusion] Thymosin al combined with antiviral drugs may improve the survival rate of patients with CMV pneumonia and it is safe and effective in the treatment of CMV pneumonia.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2007年第22期2784-2786,共3页
China Journal of Modern Medicine
关键词
肾移植CMV肺炎
胸腺肽al
治疗
kidney transplantation
eytomegalovirus pneumonia
thymosin al
therapy